Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Androgen | 7 | 2024 | 413 | 2.600 |
Why?
|
Prostatic Neoplasms | 9 | 2024 | 1547 | 2.020 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 4 | 2021 | 88 | 1.670 |
Why?
|
Androgens | 3 | 2021 | 274 | 0.800 |
Why?
|
Precision Medicine | 2 | 2022 | 319 | 0.610 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2018 | 39 | 0.570 |
Why?
|
Pyrimidinones | 1 | 2018 | 49 | 0.560 |
Why?
|
Genes, Neoplasm | 1 | 2018 | 80 | 0.560 |
Why?
|
Uveal Neoplasms | 1 | 2018 | 59 | 0.550 |
Why?
|
Neoplasms, Experimental | 1 | 2018 | 211 | 0.540 |
Why?
|
Inverted Repeat Sequences | 3 | 2010 | 13 | 0.530 |
Why?
|
Chromosomes, Fungal | 3 | 2010 | 49 | 0.520 |
Why?
|
DNA Replication | 4 | 2010 | 352 | 0.520 |
Why?
|
Chromatin | 2 | 2021 | 552 | 0.460 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 1894 | 0.380 |
Why?
|
Gene Rearrangement | 2 | 2010 | 320 | 0.380 |
Why?
|
Castration | 2 | 2021 | 33 | 0.370 |
Why?
|
Apoptosis | 1 | 2018 | 1806 | 0.360 |
Why?
|
Genes, cdc | 1 | 2010 | 25 | 0.360 |
Why?
|
Saccharomyces cerevisiae | 2 | 2010 | 426 | 0.350 |
Why?
|
Exodeoxyribonucleases | 1 | 2010 | 51 | 0.350 |
Why?
|
Melanoma | 1 | 2018 | 942 | 0.340 |
Why?
|
Saccharomyces cerevisiae Proteins | 3 | 2010 | 277 | 0.340 |
Why?
|
Metabolome | 1 | 2012 | 293 | 0.330 |
Why?
|
Neoplasms | 5 | 2024 | 2790 | 0.330 |
Why?
|
Gene Amplification | 1 | 2010 | 230 | 0.330 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 3348 | 0.280 |
Why?
|
Male | 12 | 2024 | 61501 | 0.250 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 889 | 0.230 |
Why?
|
Humans | 22 | 2024 | 125128 | 0.230 |
Why?
|
Gene Expression Regulation | 2 | 2012 | 2522 | 0.230 |
Why?
|
Repressor Proteins | 2 | 2020 | 813 | 0.220 |
Why?
|
Benzamides | 1 | 2024 | 109 | 0.220 |
Why?
|
Receptors, Glucocorticoid | 1 | 2024 | 120 | 0.220 |
Why?
|
Adenocarcinoma | 2 | 2024 | 1026 | 0.220 |
Why?
|
Nitriles | 1 | 2024 | 146 | 0.210 |
Why?
|
Liver Neoplasms | 2 | 2024 | 1314 | 0.200 |
Why?
|
Nuclear Proteins | 2 | 2020 | 1265 | 0.200 |
Why?
|
Bile Acids and Salts | 1 | 2024 | 244 | 0.190 |
Why?
|
Dilazep | 1 | 2021 | 2 | 0.190 |
Why?
|
GATA2 Transcription Factor | 1 | 2021 | 39 | 0.190 |
Why?
|
Androgen Receptor Antagonists | 1 | 2021 | 35 | 0.180 |
Why?
|
Immunity | 1 | 2022 | 192 | 0.180 |
Why?
|
Oncogenes | 1 | 2021 | 167 | 0.180 |
Why?
|
Androgen Antagonists | 1 | 2021 | 120 | 0.170 |
Why?
|
Saccharomycetales | 2 | 2010 | 37 | 0.170 |
Why?
|
Genomic Instability | 3 | 2010 | 229 | 0.170 |
Why?
|
p300-CBP Transcription Factors | 1 | 2020 | 44 | 0.170 |
Why?
|
DNA, Fungal | 2 | 2010 | 77 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 723 | 0.170 |
Why?
|
Thiophenes | 1 | 2020 | 70 | 0.160 |
Why?
|
Up-Regulation | 1 | 2022 | 867 | 0.160 |
Why?
|
Lipid Metabolism | 1 | 2022 | 357 | 0.160 |
Why?
|
Health Status Disparities | 1 | 2022 | 228 | 0.160 |
Why?
|
Mutation | 3 | 2021 | 5845 | 0.150 |
Why?
|
Prostate | 2 | 2022 | 435 | 0.150 |
Why?
|
Socioeconomic Factors | 1 | 2022 | 871 | 0.150 |
Why?
|
Peroxisomal Multifunctional Protein-2 | 1 | 2018 | 2 | 0.150 |
Why?
|
Liver Cirrhosis | 1 | 2024 | 832 | 0.140 |
Why?
|
Genomics | 2 | 2024 | 1499 | 0.140 |
Why?
|
Glucocorticoids | 1 | 2020 | 383 | 0.140 |
Why?
|
Healthcare Disparities | 1 | 2022 | 434 | 0.140 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 582 | 0.140 |
Why?
|
Protein Isoforms | 1 | 2018 | 403 | 0.130 |
Why?
|
Cell Proliferation | 3 | 2020 | 2311 | 0.130 |
Why?
|
Ubiquitination | 1 | 2017 | 167 | 0.130 |
Why?
|
Mice, Nude | 1 | 2018 | 708 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 880 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 196 | 0.120 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 930 | 0.120 |
Why?
|
Down-Regulation | 1 | 2018 | 699 | 0.120 |
Why?
|
Cell Cycle | 1 | 2018 | 617 | 0.120 |
Why?
|
Animals | 9 | 2024 | 34235 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 1691 | 0.120 |
Why?
|
Biomarkers, Tumor | 1 | 2021 | 1496 | 0.110 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2012 | 119 | 0.090 |
Why?
|
Biomarkers | 1 | 2020 | 3091 | 0.090 |
Why?
|
Checkpoint Kinase 2 | 1 | 2010 | 36 | 0.090 |
Why?
|
Checkpoint Kinase 1 | 1 | 2010 | 24 | 0.090 |
Why?
|
Replication Origin | 1 | 2010 | 11 | 0.090 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 358 | 0.090 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2010 | 86 | 0.080 |
Why?
|
DNA, Neoplasm | 1 | 2010 | 302 | 0.080 |
Why?
|
Cell Cycle Proteins | 2 | 2010 | 656 | 0.080 |
Why?
|
Protein Kinases | 1 | 2010 | 330 | 0.080 |
Why?
|
Histones | 1 | 2012 | 525 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 558 | 0.070 |
Why?
|
Genome | 1 | 2009 | 470 | 0.070 |
Why?
|
Mice | 4 | 2024 | 17633 | 0.060 |
Why?
|
Phenylthiohydantoin | 1 | 2024 | 12 | 0.060 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2024 | 32 | 0.060 |
Why?
|
Heterografts | 1 | 2024 | 173 | 0.050 |
Why?
|
Neuroendocrine Tumors | 1 | 2024 | 54 | 0.050 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2002 | 26 | 0.050 |
Why?
|
Pigment Epithelium of Eye | 1 | 2002 | 37 | 0.050 |
Why?
|
Prospective Studies | 2 | 2024 | 6150 | 0.050 |
Why?
|
Lymphoproliferative Disorders | 1 | 2024 | 225 | 0.050 |
Why?
|
Cell Lineage | 1 | 2024 | 345 | 0.050 |
Why?
|
Prognosis | 2 | 2022 | 4644 | 0.050 |
Why?
|
Cadherins | 1 | 2002 | 171 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2024 | 584 | 0.050 |
Why?
|
Medical Oncology | 1 | 2022 | 216 | 0.040 |
Why?
|
Consensus | 1 | 2024 | 641 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2024 | 1360 | 0.040 |
Why?
|
RNA-Binding Proteins | 1 | 2024 | 573 | 0.040 |
Why?
|
Acetylation | 1 | 2020 | 166 | 0.040 |
Why?
|
Molecular Docking Simulation | 1 | 2020 | 110 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2002 | 527 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 678 | 0.040 |
Why?
|
Molecular Structure | 1 | 2020 | 295 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2024 | 2173 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2020 | 581 | 0.040 |
Why?
|
Drug Discovery | 1 | 2020 | 171 | 0.040 |
Why?
|
Disease Progression | 1 | 2024 | 2067 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2024 | 1112 | 0.040 |
Why?
|
Ubiquitin-Protein Ligase Complexes | 1 | 2017 | 28 | 0.030 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2017 | 43 | 0.030 |
Why?
|
Proteasome Inhibitors | 1 | 2017 | 60 | 0.030 |
Why?
|
Survival Rate | 1 | 2021 | 2062 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2021 | 5176 | 0.020 |
Why?
|
Risk Factors | 1 | 2024 | 10314 | 0.020 |
Why?
|
DNA Breaks | 1 | 2009 | 26 | 0.020 |
Why?
|
Protein Transport | 1 | 2010 | 368 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2017 | 3744 | 0.020 |
Why?
|
Chromosomes | 1 | 2009 | 198 | 0.020 |
Why?
|
DNA Helicases | 1 | 2010 | 231 | 0.020 |
Why?
|
United States | 1 | 2024 | 10891 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2009 | 131 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2010 | 356 | 0.020 |
Why?
|
Cohort Studies | 1 | 2017 | 4811 | 0.020 |
Why?
|
Aged | 1 | 2024 | 19870 | 0.020 |
Why?
|
Middle Aged | 1 | 2024 | 26920 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2002 | 459 | 0.010 |
Why?
|
Cattle | 1 | 2002 | 568 | 0.010 |
Why?
|
Antigens, CD | 1 | 2002 | 432 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1290 | 0.010 |
Why?
|
RNA | 1 | 2002 | 570 | 0.010 |
Why?
|
Protein Binding | 1 | 2002 | 1756 | 0.010 |
Why?
|
Female | 1 | 2024 | 66781 | 0.010 |
Why?
|
Gene Expression | 1 | 2002 | 1560 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2002 | 3056 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2002 | 1527 | 0.010 |
Why?
|